Customers of 23andMe Face Uncertain Future Amid Company’s Financial Woes
According to a recent New York Times article, customers of genetic data company 23andMe may be facing greater risks than they realize. The article suggests that while the company’s current troubles may be short-lived, the potential long-term threats to the roughly 15 million people who have used their services could be significant if 23andMe is unable to continue operating.
Founder and CEO Anne Wojcicki’s hopes of turning around 23andMe seem to be fading with each passing day. The company, which was valued at $6 billion when it went public in 2021, is now valued at just $150 million and is at risk of being delisted next month. Negative press coverage is only adding to the company’s challenges.
Despite assurances from 23andMe that they will continue to comply with data regulations, there are concerns about the security of the sensitive genetic information they collect. A Yale biomedical professor highlighted the fact that while hacked credit cards can be replaced, a compromised genome cannot. Additionally, advancements in genome analysis technology mean that the information gathered from genetic testing is becoming increasingly detailed and revealing.
